2022年欧洲肿瘤内科学会ESMO乳腺癌大会

欧洲肿瘤内科学会(ESMO)诚挚地邀请您参加将于2022年5月3日至5日在德国柏林举行的ESMO乳腺癌大会。ESMO乳腺癌年会是在欧洲举行的一个多学科全球会议，由全球公认的一流专家参与，是所有对创新、转化肿瘤学和护理感兴趣的乳腺癌研究人员和临床医生的进行交流的平台，预计有超过800名专业人士出席会议。

欧洲肿瘤内科学会（ESMO）成立于1975年，是欧洲领先的肿瘤内科学专业组织，现在全球150多个国家和地区拥有超过23,000名会员，是肿瘤学教育和信息的参考学会，ESMO致力于支持其会员在快速发展的专业环境中得到宣发展与进步。作为一个非营利组织，ESMO一直以推动癌症护理和治疗为使命，致力于推进肿瘤医学专业的发展，以多学科的方法来促进癌症的治疗和护理。

ESMO BREAST CANCER CONGRESS 2022
Berlin, Germany
03-05 May 2022

Cancer patients and their needs are at the heart of what we do – we are committed to advancing research and integrating it into the clinic to ensure better care for our patients. 

We aim to deliver a comprehensive overview of all the practice-changing new data and to make sure it has a clear roadmap to the clinic.

We count on you to take part and we look forward to welcoming you once again to ESMO Breast Cancer, a multidisciplinary meeting where you will learn how to integrate innovation into your daily practice and improve patient care.

摘要：

Abstract submission deadlines

点此提交摘要>>>Submit Abstract>>>

Outcome notifications

Outcome notifications are expected to be made available to first authors by mid-March 2022.

Late-breaking abstracts

*A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline (15 February 2022).

Final versions must be submitted by 5 April 2022, 21:00 CEST (Central European Summer Time).

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ESMO Breast Cancer 2022.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 15 February 2022 will be considered for late-breaking status.

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2022.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

• Background
• Trial design

Notes:

• Recruitment must have already begun or have been completed by the abstract submission deadline of 15 February 2022.
• Abstracts including results or preliminary data will be rejected.
• Authors of ‘encore’ TiP abstract submissions must supply information regarding the original presentation, indicating the name of the meeting and publication number. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s).
• Trial in Progress abstracts will be accepted for Poster outcome only.

Presentation of accepted abstracts

The ESMO Breast Cancer 2022 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:

• Proffered Paper (oral presentation) – Full oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini oral – Short oral presentation by the authors with comment and interactive audience discussion led by an invited expert.
• Poster – An important method for communicating details of scientific research, posters will be on display for the duration of the Congress.

Publications

All accepted abstracts will be published as a supplement to the official ESMO journal Annals of Oncology.

Travel grants

A restricted number of travel grants to the ESMO Breast Cancer Congress 2022 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the ESMO Breast Cancer 2022 Scientific Committee on a competitive basis from among the accepted abstracts.

The application for an ESMO Travel Grant must be completed during the abstract submission process. Applicants will be required to reply to the following questions:

• How relevant to your current practice are the topics presented at this Congress?
• Have you attended any event on a similar topic in the last 3 years?
• How will attendance at this Congress help with your professional development?
• How can your abstract contribute to the topics covered at this Congress?
• Have you recently been awarded an ESMO Award/Travel Grant? If yes, for which event?